Alterity Therapeutics (ATHE) Other Non-Current Assets (2009 - 2016)
Alterity Therapeutics (ATHE) posted quarterly Other Non-Current Assets of $32998.0 for Q4 2016, up 0.85% year-over-year from $32718.6 in Q1 2016, and little changed quarter-over-quarter from $32845.9 in Q2 2016.
Alterity Therapeutics (ATHE) Other Non-Current Assets (2009 - 2016) Analysis & Trends
Alterity Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $32998.0 for Q4 2016.
- In Q4 2016, Other Non-Current Assets rose 0.85% year-over-year to $32998.0; the TTM figure through Dec 2016 stood at $32998.0 (up 0.85% YoY), while the FY2016 annual figure was $32998.0, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2016 stood at $32998.0, roughly flat from $32845.9 in the prior quarter.
- The five-year high for Other Non-Current Assets was $43699.5 in Q2 2013, with the low at $32718.6 in Q4 2015.
- The 5-year median for Other Non-Current Assets is $37931.7 (2012), against an average of $37458.4.
- The sharpest annual moves came in 2013 and 2015: Other Non-Current Assets gained 14.29% in 2013, then declined 13.84% in 2015.
- Alterity Therapeutics' Other Non-Current Assets stood at $39286.3 in 2012, then grew by 3.88% to $40810.8 in 2013, then decreased by 7.8% to $37627.8 in 2014, then retreated by 13.05% to $32718.6 in 2015, then advanced by 0.85% to $32998.0 in 2016.
- Business Quant data shows ATHE's Other Non-Current Assets at $32998.0 in Q4 2016, $32845.9 in Q2 2016, and $32718.6 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 32,997.97 |
| Jun 30, 2016 | 32,845.95 |
| Dec 31, 2015 | 32,718.55 |
| Jun 30, 2015 | 35,343.19 |
| Dec 31, 2014 | 37,627.80 |
| Jun 30, 2014 | 41,018.70 |
| Dec 31, 2013 | 40,810.81 |
| Jun 30, 2013 | 43,699.45 |
| Dec 31, 2012 | 39,286.30 |
| Jun 30, 2012 | 38,235.56 |
| Dec 31, 2011 | 38,255.11 |
| Jun 30, 2011 | 40,170.93 |
| Dec 31, 2010 | 35,164.00 |
| Jun 30, 2010 | 31,086.25 |
| Dec 31, 2009 | 35,164.00 |
| Jun 30, 2009 | 26,687.62 |